<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01055678</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00020382</org_study_id>
    <secondary_id>R01CA040355</secondary_id>
    <nct_id>NCT01055678</nct_id>
  </id_info>
  <brief_title>To Evaluate the Characteristics of a Breast Cancer</brief_title>
  <official_title>Pilot Study to Characterize the HRHV Axis in the Microenvironment of Breast Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mark Dewhirst</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to determine the prevalence of markers of chronic and
      cycling hypoxia and reactive species stress (oxidative and nitrosative) in the breast cancer
      tumor microenvironment. The study is based around four cornerstone features of the pathologic
      microenvironment - Hypoxia, Reactive Species (reactive oxygen and nitrogen species), HIF-1
      and VEGF, which we term the HRHV axis. Fifty breast cancer patients with planned surgical
      excision will be administered the hypoxia marker drug, EF5, 24-36 hr prior to surgical
      excision. EF5 is a non-therapeutic drug and provides no direct benefit to those patients
      enrolled in this pilot study. Tissues obtained intra-operatively will be snap frozen and
      subsequently analyzed for EF5 binding. Immunohistochemical analysis of a cohort of
      immunohistochemical and urine markers that depict the HRHV axis will be examined. The
      association of the markers with the presence of hypoxia, as determined by EF5 positivity,
      will be determined. Data from this pilot study will be used to establish the prevalence of
      markers of the HRHV axis in breast cancer. This information will be crucial for future human
      trials in which the HRHV axis is therapeutically targeted.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI left Duke
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate tumor characteristics</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra and Interpatient correlations with tumor hypoxia</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>All Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm study analyzing tumor hypoxia after EF5 injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EF5</intervention_name>
    <description>An infusion of EF5, a fluorinated 2-nitroimidazole, will be administered using the recommended dose of 21mg/kg one day prior to surgical procedure.</description>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Partial or Total Mastectomy</intervention_name>
    <description>A small tissue sample will be removed from the excised tissue and will be stored for later analysis.</description>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed Stage 0 - III invasive carcinoma of the breast

          -  Tumor size greater than 1-cm by radiological (mammogram/ultrasound or MRI) evaluation

          -  KPS status ≥ 70

          -  Bilirubin ≤ 1.5x normal

          -  Creatinine ≤ 1.8

          -  WBC &gt; 3000/mm^3 and platelets &gt; 100,000/mm^3

        Exclusion Criteria:

          -  Pregnant or breast-feeding women

          -  Neoadjuvant chemo or hormonal therapy for existent breast malignancy

          -  Allergy to IV contrast dye

          -  History of grade III or IV peripheral neuropathy as defined by the NCI CTC

          -  Previous history of any malignancy treated with radiotherapy and/or chemohormonal
             therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark W Dewhirst, DVM, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 2008 Jun;8(6):425-37. doi: 10.1038/nrc2397. Review. Erratum in: Nat Rev Cancer. 2008 Aug;8(8):654.</citation>
    <PMID>18500244</PMID>
  </reference>
  <reference>
    <citation>Koch CJ, Hahn SM, Rockwell K Jr, Covey JM, McKenna WG, Evans SM. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles. Cancer Chemother Pharmacol. 2001 Sep;48(3):177-87.</citation>
    <PMID>11592338</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2010</study_first_submitted>
  <study_first_submitted_qc>January 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2010</study_first_posted>
  <last_update_submitted>December 14, 2012</last_update_submitted>
  <last_update_submitted_qc>December 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Mark Dewhirst</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>ductal breast carcinoma in situ</keyword>
  <keyword>breast cancer in situ</keyword>
  <keyword>invasive carcinoma</keyword>
  <keyword>invasive ductal carcinoma</keyword>
  <keyword>invasive lobular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

